CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-01 | Sethuraman Natarajan Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +66,800 | 66,800 | ||
| 2024-02-15 | Doshi Dipal CEO | Sale 10b5-1 | −1,000 | $15.00 | $15K | 243,279 |
| 2024-01-16 | Doshi Dipal CEO | Sale 10b5-1 | −1,000 | $15.99 | $16K | 244,279 |
| 2023-12-26 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise 10b5-1 | +94 | $2.10 | $197 | 49,665 |
| 2023-12-26 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −94 | $16.67 | $2K | 49,571 |
| 2023-12-26 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −94 | 52,157 | ||
| 2023-12-22 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise 10b5-1 | +10,206 | $2.10 | $21K | 59,777 |
| 2023-12-22 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −6,529 | $15.24 | $100K | 53,248 |
| 2023-12-22 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −3,677 | $16.48 | $61K | 49,571 |
| 2023-12-22 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,206 | 52,251 | ||
| 2023-12-21 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise 10b5-1 | +2,200 | $2.10 | $5K | 51,771 |
| 2023-12-21 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −2,200 | $15.07 | $33K | 49,571 |
| 2023-12-21 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,200 | 62,457 | ||
| 2023-12-20 | Doshi Dipal President and CEO | Sale 10b5-1 | −1,000 | $15.00 | $15K | 245,279 |
| 2023-11-13 | Doshi Dipal President and CEO | Sale 10b5-1 | −1,000 | $16.23 | $16K | 246,279 |
| 2023-10-17 | Doshi Dipal President and CEO | Sale 10b5-1 | −1,000 | $15.00 | $15K | 247,279 |
| 2023-09-13 | Doshi Dipal President and CEO | Sale 10b5-1 | −1,000 | $15.00 | $15K | 248,279 |
| 2023-09-06 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −904 | $13.45 | $12K | 49,617 |
| 2023-09-06 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −46 | $14.03 | $645 | 49,571 |
| 2023-09-06 | KREHER NERISSA Chief Medical Officer | Sale 10b5-1 | −871 | $13.46 | $12K | 40,058 |
Page 13 of 26 · 517 trades